[Federal Register Volume 84, Number 104 (Thursday, May 30, 2019)] [Notices] [Page 25060] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2019-11313] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2018-D-1456] Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-the-Counter Monograph: Study Elements and Considerations; Guidance for Industry; Availability; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration is correcting a notice entitled ``Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-the-Counter Monograph: Study Elements and Considerations; Guidance for Industry; Availability'' that appeared in the Federal Register of May 10, 2019. The document announced the availability of a guidance for industry. The document was published with the incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Kristen Hardin, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5443, Silver Spring, MD 20993-0002, 240- 402-4246. SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, May 10, 2019 (84 FR 20633), in FR Doc. 2019-09692, the following correction is made: On page 20633, in the first column, in the headings of the document, ``[Docket No. FDA-2019-D-1798]'' is corrected to read ``[Docket No. FDA-2018-D-1456].'' Dated: May 24, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019-11313 Filed 5-29-19; 8:45 am] BILLING CODE 4164-01-P